A randomized double-blind controlled trial (TRIPLE study [16]) was conducted to verify the prophylactic antiemetic effect of APR as part of a combination antiemetic regimen expected to be effective during the delayed phase of CINV. The primary endpoint of the TRIPLE study was a complete response (CR; no vomiting/retching and no rescue medication) within 120 h after the initiation of cisplatin treatment. Eligible patients were randomly allocated to double-blind treatment with either GRA (1 mg) or PALO (0.75 mg) as part of triplet antiemetic regimens for cisplatin-based HEC.
Although the primary endpoint was not met and the superiority of PALO was not demonstrated in this clinical trial (P = 0.0539), PALO displayed efficacy superior to GRA in terms of controlling CINV, especially in the delayed phase.
No previous study directly compared the cost-effectiveness of GRA and PALO, both in combination with APR and DEX, in preventing CINV in patients treated with cisplatin-based chemotherapy in terms of the detailed cost of antiemetics including rescue medication. As price information is available for all drugs covered by Japan’s health insurance program, it is possible to clarify the drug costs of antiemetics used by various patient groups and the cost-effectiveness ratio (CER) per instance of vomiting suppression as economic evidence. This research sought to clarify the cost-effectiveness of the triple antiemetic combinations and conduct real-world cost analysis using data from the TRIPLE study.
Methods

Patients

In total, 827 patients receiving cisplatin-based HEC enrolled in a randomized, double-blind, multicenter phase III trial to validate the superiority of PALO (0.75 mg) over GRA (1 mg) were evaluated. The study design details and primary results of our phase III trial were described previously [16].

### Language ###
English

### Assessment ###
This text is about clinical trial comparing antiemetic drugs - we could ask about the total number of patients involved.

### Query ###
Tell me the number of patients enrolled in the PALO vs GRA clinical trial.

Note: This query is built with an original syntax starting with "Tell me" instead of a typical "what/how many" question format, while seeking precise factual information provided in the text (827 patients).
Tell me the number of patients enrolled in the PALO vs GRA clinical trial.

Note: This query is built with an original syntax starting with "Tell me" instead of a typical "what/how many" question format, while seeking precise factual information provided in the text (827 patients).